These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31114351)

  • 21. Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.
    Wei Y; He L; Liu T; Guo T; Xie C; Jia J; Lin Y; Liu J; Fan J
    Front Pharmacol; 2024; 15():1372077. PubMed ID: 38584601
    [No Abstract]   [Full Text] [Related]  

  • 22. Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study.
    Majić A; Miše BP; Matković V; Belac Lovasić I; Katić K; Canjko I; Frobe A; Bajić Ž; Vrdoljak E
    J Oncol; 2020; 2020():6423936. PubMed ID: 32655639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of combination of poly-ADP-ribose polymerase inhibitor (PARPi) and chemotherapy compared with chemotherapy alone in treatment of recurrent ovarian carcinoma: a systematic review.
    Adamu SM; Oyewole OS; Kabir UF
    Niger Med J; 2024; 65(1):1-15. PubMed ID: 39006180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olaparib (LYNPARZAO) Ovarian cancer: spare patients who are in remission.
    Prescrire Int; 2017 Jan; 26(178):9-12. PubMed ID: 30730634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials.
    Ruiz-Schutz VC; Gomes LM; Mariano RC; de Almeida DVP; Pimenta JM; Dal Molin GZ; Kater FR; Yamamura R; Correa Neto NF; Maluf FC; Schutz FA
    Crit Rev Oncol Hematol; 2019 Sep; 141():163-173. PubMed ID: 31306986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
    Moore KN; Monk BJ
    Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Olaparib Tablet: A Review in Ovarian Cancer Maintenance Therapy.
    Heo YA; Dhillon S
    Target Oncol; 2018 Dec; 13(6):801-808. PubMed ID: 30456461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.
    Friedlander M; Banerjee S; Mileshkin L; Scott C; Shannon C; Goh J
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):323-331. PubMed ID: 27917619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combinational use of trabectedin and pegylated liposomal doxorubicin for recurrent ovarian cancer: a meta-analysis of phase III randomized controlled trials.
    Li C; Qiao S; Kang M; Gao X; Li Z
    Am J Transl Res; 2023; 15(12):6675-6689. PubMed ID: 38186978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
    Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A
    Lancet; 2010 Jul; 376(9737):245-51. PubMed ID: 20609468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study.
    Bellier C; Gladieff L; Le Du F; Berton D; Bonnard C; Suau D; Richard AC; Brenner O; Lahouegue A; Freyer G; Floquet A; Frank S; Kfoury M
    Drugs Real World Outcomes; 2023 Jun; 10(2):207-213. PubMed ID: 36630055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiangiogenesis therapy in ovarian cancer patients: An updated meta-analysis for 15 randomized controlled trials.
    Jiang Y; Sun X; Kong B; Jiang J
    Medicine (Baltimore); 2018 Aug; 97(34):e11920. PubMed ID: 30142803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poly (ADP-ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: A Drug Class Review.
    Ringley JT; Moore DC; Patel J; Rose MS
    P T; 2018 Sep; 43(9):549-556. PubMed ID: 30186027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer.
    Frampton JE
    BioDrugs; 2015 Apr; 29(2):143-50. PubMed ID: 25899311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China.
    Zhang D; Li S; Zhang X; Peng J; Zhang S
    Front Oncol; 2022; 12():955124. PubMed ID: 36059631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed,
    Kristeleit RS; Oaknin A; Ray-Coquard I; Leary A; Balmaña J; Drew Y; Oza AM; Shapira-Frommer R; Domchek SM; Cameron T; Maloney L; Goble S; Lorusso D; Ledermann JA; McNeish IA
    Int J Gynecol Cancer; 2019 Nov; 29(9):1396-1404. PubMed ID: 31685558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials.
    Hao J; Liu Y; Zhang T; He J; Zhao H; An R; Xue Y
    Crit Rev Oncol Hematol; 2021 Jan; 157():103145. PubMed ID: 33254040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations.
    Moore KN; Birrer MJ
    Oncologist; 2018 Jun; 23(6):697-703. PubMed ID: 29593098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials.
    Wang Y; Ren F; Song Z; Wang X; Zhang C; Ouyang L
    Front Oncol; 2020; 10():1204. PubMed ID: 32850351
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer.
    Jiang Y; Zhao J; Zhang L; Tian S; Yang T; Wang L; Zhao M; Yang Q; Wang Y; Yang X
    Front Oncol; 2020; 10():954. PubMed ID: 32719741
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.